Does 1p/19q testing have no significance in the workup of glioblastomas?
These data suggest that (i) 1p/19q testing is not useful on gliomas that are histologically GBMs; (ii) codeletion testing should be reserved only for cases with compatible morphology; and (iii) EGFR, 10q, and IDH1 testing can help act as safeguards against a false-positive 1p/19q result.
Toll-like receptor signaling 4 may induce placental CRH expression through MyD88.